

LIFECARE Q1 2024 REPORT AND WEBCAST

Lifecare AS will present Q1 2024 financial and operational status in a webcast Wednesday 8 May. The webcast will be for all shareholders and interested parties at 11:00 – 11:45 CET.

Lifecare's CEO Joacim Holter presents the company's Q1 report followed by a Q&A session where Holter will answer questions submitted in advance. Questions in connection with the Q1 report can be sent to the e-mail addresses listed below. Unfortunately, we must take the liberty of moderating the number of questions due to time constraints.

The webcast will be available here:

[Join the Microsoft TEAMS meeting](#)

https://teams.microsoft.com/join/19%3ameeting_MmI5OWI3ZjQtMDJkZS00NzIxLTg3NjctYTJhODhiNWM2Y2I5%40thread.v2/0?context=%7b%22id%22%3a%22c5fb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d

About us

Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52